Peter concentrates his practice on US and international patent prosecution and strategic counseling on patent issues, primarily for clients in the biotechnology industry. He regularly conducts patentability, non-infringement, and freedom to operate analyses and performs IP due diligence for financing and acquisitions. Peter has experience with a variety of technologies, including large- and small-molecule therapeutics, CRISPR, and diagnostics.

Prior to joining Mintz, Peter was an associate at an international law firm and at a US-based law firm, where he handled patent matters related to biotechnology, therapeutics, and diagnostics and performed IP diligence.

While earning his JD, Peter served as executive editor of the Brigham Young University Law Review and as an extern for the US Court of Appeals for the Tenth Circuit.

Before law school, Peter worked as a postdoc. He concentrated his research on cardiovascular metabolism, studying how whole-body metabolism affects the heart at the University of California, San Francisco, and microRNA effects on heart health at Washington University in St. Louis. His PhD dissertation focused on glucose 6-phosphate dehydrogenase deficiency, macronutrient intake, and heart failure, and aimed at determining the effects of NADPH production on heart failure development, particularly when a person’s heart failure is exacerbated by high sugar intake.